KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Common Equity (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Common Equity data on record, last reported at $4.0 billion in Q3 2025.

  • For Q3 2025, Common Equity fell 5.08% year-over-year to $4.0 billion; the TTM value through Sep 2025 reached $4.0 billion, down 5.08%, while the annual FY2024 figure was $4.1 billion, 9.55% up from the prior year.
  • Common Equity reached $4.0 billion in Q3 2025 per JAZZ's latest filing, up from $3.7 billion in the prior quarter.
  • Across five years, Common Equity topped out at $4.2 billion in Q1 2025 and bottomed at $2.7 billion in Q3 2022.
  • Average Common Equity over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 35.22% in 2021, then plummeted 30.3% in 2022.
  • A 5-year view of Common Equity shows it stood at $4.0 billion in 2021, then decreased by 22.18% to $3.1 billion in 2022, then rose by 21.11% to $3.7 billion in 2023, then rose by 9.55% to $4.1 billion in 2024, then decreased by 3.29% to $4.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $4.0 billion in Q3 2025, $3.7 billion in Q2 2025, and $4.2 billion in Q1 2025.